ArticleFrontiers in oncology2026
Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Autologous stem cell transplantation (ASCT) for the treatment of multiple myeloma and lymphoma patients has been reported to improve relapse-free (RFS) and overall survival (OS). Nonetheless, the impact on patient-reported outcomes, such as professional activity and health-related quality of life (HRQoL) remains unclear. Patients and methods: In a cross-sectional two-center study, we collected data of 122 patients receiving high-dose chemotherapy followed by ASCT for multiple myeloma (MM) or lymphoma between 2007 and 2023 at two German tertiary care centers through standardized questionnaires. Results: The median age of all patients at diagnosis was 56 years (range 24-67 years). 17.9% of patients received a second ASCT. 55.0% and 61.9% of patients achieved a complete remission after first and second ASCT, respectively. The median time to resumption of employment was 167 days and the overall rate of return to work (RTW) was 56.0%. Following ASCT, 29.0% of patients reduced their working hours and 95.4% had a recognized disability status.The median quality of life/health status QLQ-C30 score after ASCT was 66.7 out of 100. A QoL/health status of < 50 was significantly associated with a lower rate of resumption of professional activity (HR 0.44, 95% CI: 0.26-0.78, p = 0.02). 86.0% of all patients reported fatigue symptoms. The QLQ-MY20 score for fears of the future was significantly higher than for disease symptoms and therapy side effects (p < 0.0001), indicating that after ASCT, psychological symptoms affected patients more than somatic aspects. Conclusion: Our study suggests that long-term toxicities of ASCT significantly impact patients' HRQoL and impair their professional activity. Treatment should include an assessment of mental health and socioeconomic status and provide necessary support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.